Simon L Goodman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4061838/publications.pdf

Version: 2024-02-01

61984 110387 10,054 61 43 64 citations h-index g-index papers 65 65 65 10007 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Crystal Structure of the Extracellular Segment of Integrin $\hat{l}\pm V\hat{l}^2$ 3 in Complex with an Arg-Gly-Asp Ligand. Science, 2002, 296, 151-155.	12.6	1,529
2	Crystal Structure of the Extracellular Segment of Integrin αVÎ ² 3. Science, 2001, 294, 339-345.	12.6	1,202
3	N-Methylated Cyclic RGD Peptides as Highly Active and Selective $\hat{l}\pm V\hat{l}^2$ 3 Integrin Antagonists. Journal of Medicinal Chemistry, 1999, 42, 3033-3040.	6.4	788
4	Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin $\hat{l}\pm V\hat{l}^2$ 3Antagonists. Journal of the American Chemical Society, 1996, 118, 7461-7472.	13.7	581
5	Structure and mechanics of integrin-based cell adhesion. Current Opinion in Cell Biology, 2007, 19, 495-507.	5.4	368
6	Integrins as therapeutic targets. Trends in Pharmacological Sciences, 2012, 33, 405-412.	8.7	340
7	Surface Coating with Cyclic RGD Peptides Stimulates Osteoblast Adhesion and Proliferation as well as Bone Formation. ChemBioChem, 2000, 1, 107-114.	2.6	285
8	Decreased angiogenesis and arthritic disease in rabbits treated with an $\hat{l}\pm\nu\hat{l}^2$ 3 antagonist. Journal of Clinical Investigation, 1999, 103, 47-54.	8.2	285
9	Multimeric Cyclic RGD Peptides as Potential Tools for Tumor Targeting: Solid-Phase Peptide Synthesis and Chemoselective Oxime Ligation. Chemistry - A European Journal, 2003, 9, 2717-2725.	3.3	252
10	Invasion patterns in brain metastases of solid cancers. Neuro-Oncology, 2013, 15, 1664-1672.	1.2	191
11	Nanomolar Small Molecule Inhibitors for $\hat{l}\pm\nu\hat{l}^2$ 6, $\hat{l}\pm\nu\hat{l}^2$ 5, and $\hat{l}\pm\nu\hat{l}^2$ 3 Integrins. Journal of Medicinal Chemistry, 2002, 45, 1045-1051.	6.4	183
12	ÂvÂ3 and αvÎ ² 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis, 2003, 6, 105-119.	7.2	183
13	Inhibition of Integrin $\hat{l}\pm v\hat{l}^26$ on Cholangiocytes Blocks Transforming Growth Factor- \hat{l}^2 Activation and Retards Biliary Fibrosis Progression. Gastroenterology, 2008, 135, 660-670.	1.3	177
14	Integrins as Therapeutic Targets: Successes and Cancers. Cancers, 2017, 9, 110.	3.7	177
15	Coming to grips with integrin binding to ligands. Current Opinion in Cell Biology, 2002, 14, 641-652.	5.4	172
16	New insights into the structural basis of integrin activation. Blood, 2003, 102, 1155-1159.	1.4	170
17	Three-dimensional EM structure of the ectodomain of integrin $\hat{l}\pm V\hat{l}^23$ in a complex with fibronectin. Journal of Cell Biology, 2005, 168, 1109-1118.	5.2	166
18	Crystal structure of the complete integrin $\hat{l}\pm V\hat{l}^23$ ectodomain plus an $\hat{l}\pm/\hat{l}^2$ transmembrane fragment. Journal of Cell Biology, 2009, 186, 589-600.	5.2	163

#	Article	IF	CITATIONS
19	Pharmacological inhibition of integrin $\hat{l}\pm v\hat{l}^2$ 3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology, 2009, 50, 1501-1511.	7.3	154
20	Immunohistochemical analysis of integrin $\hat{l}\pm\nu\hat{l}^23$ expression on tumor-associated vessels of human carcinomas. , 1997, 71, 320-324.		151
21	Cell-cell interaction and polarity of epithelial cells: Specific perturbation using a monoclonal antibody. Cell, 1983, 35, 667-675.	28.9	147
22	Cyclic RGD Peptides Containing \hat{I}^2 -Turn Mimetics. Journal of the American Chemical Society, 1996, 118, 7881-7891.	13.7	140
23	Definition of an Unexpected Ligand Recognition Motif for $\hat{l}\pm\nu\hat{l}^2$ 6 Integrin. Journal of Biological Chemistry, 1999, 274, 1979-1985.	3.4	126
24	Carbohydrate Derivatives for Use in Drug Design: Cyclicl±v-Selective RGD Peptides. Angewandte Chemie - International Edition, 2000, 39, 2761-2764.	13.8	120
25	Radiation sensitization of glioblastoma by cilengitide has unanticipated scheduleâ€dependency. International Journal of Cancer, 2009, 124, 2719-2727.	5.1	120
26	CYR61 and $\hat{l}\pm V\hat{l}^2$ 5 Integrin Cooperate to Promote Invasion and Metastasis of Tumors Growing in Preirradiated Stroma. Cancer Research, 2008, 68, 7323-7331.	0.9	109
27	Solid-Phase Synthesis of a Nonpeptide RGD Mimetic Library:  New Selective αvβ3 Integrin Antagonists. Journal of Medicinal Chemistry, 2001, 44, 1938-1950.	6.4	105
28	Structural basis for pure antagonism of integrin $\hat{l}\pm V\hat{l}^23$ by a high-affinity form of fibronectin. Nature Structural and Molecular Biology, 2014, 21, 383-388.	8.2	104
29	Titanium Implant Materials with Improved Biocompatibility through Coating with Phosphonate-Anchored Cyclic RGD Peptides. ChemBioChem, 2005, 6, 2034-2040.	2.6	103
30	Integrin control of the transforming growth factor- \hat{l}^2 pathway in glioblastoma. Brain, 2013, 136, 564-576.	7.6	94
31	αvâ€Integrin isoform expression in primary human tumors and brain metastases. International Journal of Cancer, 2013, 133, 2362-2371.	5.1	94
32	A Novel Adaptation of the Integrin PSI Domain Revealed from Its Crystal Structure. Journal of Biological Chemistry, 2004, 279, 40252-40254.	3.4	84
33	Novel Solid-Phase Synthesis of Azapeptides and Azapeptoides via Fmoc-Strategy and Its Application in the Synthesis of RGD-Mimetics. Journal of Organic Chemistry, 1999, 64, 7388-7394.	3.2	82
34	Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCEâ€MRI in a longitudinal <i>in vivo</i> study. International Journal of Cancer, 2011, 128, 2453-2462.	5.1	78
35	Integrins, cations and ligands: making the connection. Journal of Thrombosis and Haemostasis, 2003, 1 , $1642-1654$.	3.8	71
36	Matched rabbit monoclonal antibodies against $\hat{l}\pm v$ -series integrins reveal a novel $\hat{l}\pm v\hat{l}^2$ 3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biology Open, 2012, 1, 329-340.	1.2	70

3

#	Article	IF	CITATIONS
37	Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin $\hat{l}\pm v\hat{l}^23$ in Angiogenesis In vitro: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and $\hat{l}\pm v\hat{l}^23$ Are Critical. Cancer Research, 2005, 65, 9377-9387.	0.9	65
38	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget, 2016, 7, 15018-15032.	1.8	62
39	Design of superactive and selective integrin receptor antagonists containing the RGD sequence. International Journal of Peptide Research and Therapeutics, 1995, 2, 155-160.	0.1	57
40	Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. Journal of Hepatology, 2007, 46, 878-887.	3.7	56
41	Control of cell locomotion: perturbation with an antibody directed against specific glycoproteins. Cell, 1985, 41, 1029-1038.	28.9	51
42	$\hat{l}\pm v\hat{l}^23$, $\hat{l}\pm v\hat{l}^25$ and $\hat{l}\pm v\hat{l}^26$ integrins in brain metastases of lung cancer. Clinical and Experimental Metastasis, 2014, 31, 841-851.	3.3	51
43	Integrins $\hat{l}\pm v\hat{l}^2$ 3 and $\hat{l}\pm v\hat{l}^2$ 5 as prognostic, diagnostic, and therapeutic targets in gastric cancer. Gastric Cancer, 2015, 18, 784-795.	5.3	50
44	Longitudinal Expression Analysis of $\hat{l}\pm\nu$ Integrins in Human Gliomas Reveals Upregulation of Integrin $\hat{l}\pm\nu\hat{l}^23$ as a Negative Prognostic Factor. Journal of Neuropathology and Experimental Neurology, 2013, 72, 194-210.	1.7	46
45	Neovascular Targeting with Cyclic RGD Peptide (cRGDf-ACHA) to Enhance Delivery of Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 71-79.	1.0	42
46	Immunohistochemical analysis of integrins $\hat{l}\pm\nu\hat{l}^23$, $\hat{l}\pm\nu\hat{l}^25$ and $\hat{l}\pm5\hat{l}^21$, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Experimental and Therapeutic Medicine, 2011, 2, 9-19.	1.8	42
47	Circulating and imaging markers for angiogenesis. Angiogenesis, 2008, 11, 321-335.	7.2	40
48	Improving Implant Materials by Coating with Nonpeptidic, Highly Specific Integrin Ligands. Angewandte Chemie - International Edition, 2004, 43, 6649-6652.	13.8	39
49	The antibody horror show: an introductory guide for the perplexed. New Biotechnology, 2018, 45, 9-13.	4.4	34
50	Nonpeptidic $\hat{l}\pm v\hat{l}^2$ 3 Integrin Antagonist Libraries: On-Bead Screening and Mass Spectrometric Identification without Tagging. Angewandte Chemie - International Edition, 2001, 40, 165-169.	13.8	33
51	Atomic Basis for the Species-specific Inhibition of $\hat{l}\pm V$ Integrins by Monoclonal Antibody 17E6 Is Revealed by the Crystal Structure of $\hat{l}\pm V\hat{l}^2$ 3 Ectodomain-17E6 Fab Complex. Journal of Biological Chemistry, 2014, 289, 13801-13809.	3.4	32
52	Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. International Journal of Cancer, 2006, 118, 755-764.	5.1	30
53	Comparing the expression of integrins $\hat{l}\pm v\hat{l}^23$, $\hat{l}\pm v\hat{l}^25$, $\hat{l}\pm v\hat{l}^26$, $\hat{l}\pm v\hat{l}^28$, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors. International Journal of Clinical and Experimental Pathology, 2013, 6, 2719-32.	0.5	29
54	The Antibody Society's antibody validation webinar series. MAbs, 2020, 12, 1794421.	5.2	26

#	Article	IF	CITATIONS
55	Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 69-78.	2.8	25
56	Purification, Analysis, and Crystal Structure of Integrins. Methods in Enzymology, 2007, 426, 307-336.	1.0	16
57	The path to VICTORy $\hat{a}\in$ a beginner's guide to success using commercial research antibodies. Journal of Cell Science, 2018, 131, .	2.0	10
58	The $\hat{l}\pm V\hat{l}^23/\hat{l}\pm V\hat{l}^25$ integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model. International Journal of Cancer, 2013, 132, 2694-2704.	5.1	9
59	Validation and Comparison of Anti- $\hat{l}\pm v\hat{l}^2$ 3 and Anti- $\hat{l}\pm v\hat{l}^2$ 5 Rabbit Monoclonal Versus Murine Monoclonal Antibodies in Four Different Tumor Entities. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 553-560.	1.2	9
60	Divalent cations and the relationship between $\hat{l}_{\pm}A$ and $\hat{l}_{\pm}A$ domains in integrins. Biochemical Pharmacology, 2002, 64, 805-812.	4.4	4
61	Piltdown wasn't cricket but does the hobbit ring true?. Nature, 2006, 443, 394-394.	27.8	1